Physician profile
Alejandro Pedrozo
NPI 1689626236
$3,094.66
in general payments reported to CMS, 2019-2025
20 companies · $719 in 2025
The $719 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $219 · 2021: $522 · 2022: $484 · 2023: $145 · 2024: $585 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $825.37 | 2019-2025 | |
| Incyte Corporation | $448.96 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $426.47 | 2019-2025 | Bimzelx |
| Abbvie INC. | $421.43 | 2019-2024 | |
| Pfizer INC. | $329.68 | 2019-2025 | |
| Janssen Biotech, INC. | $145.75 | 2021-2022 | |
| Genentech USA, INC. | $125.17 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $66.05 | 2021 | |
| Merck Sharp & Dohme LLC | $51.64 | 2019 | |
| Galderma Laboratories, L.P. | $49.59 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $40.38 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $30.20 | 2022 | |
| Lilly USA, LLC | $23.44 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.33 | 2020 | |
| Phadia US INC. | $19.12 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.48 | 2019 | |
| Dermavant Sciences, INC. | $18.19 | 2023 | Vtama |
| Nabriva Therapeutics, Plc | $17.83 | 2021 | |
| Organogenesis INC. | $16.58 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Pedrozo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.